Synthesizing 7T Susceptibility Weighted Imaging (SWI) from 3T SWI could offer significant clinical benefits by combining the high sensitivity of 7T SWI for neurological disorders with the widespread availability of 3T SWI in diagnostic routines. Although methods exist for synthesizing 7T Magnetic Resonance Imaging (MRI), they primarily focus on traditional MRI modalities like T1-weighted imaging, rather than SWI. SWI poses unique challenges, including limited data availability and the invisibility of certain tissues in individual 3T SWI slices. To address these challenges, we propose a Self-supervised Anatomical Continuity Enhancement (SACE) network to synthesize 7T SWI from 3T SWI using plentiful 3T SWI data and limited 3T-7T paired data. The SACE employs two specifically designed pretext tasks to utilize low-level representations from abundant 3T SWI data for assisting 7T SWI synthesis in a downstream task with limited paired data. One pretext task emphasizes input-specific morphology by balancing the elimination of redundant patterns with the preservation of essential morphology, preventing the blurring of synthetic 7T SWI images. The other task improves the synthesis of tissues that are invisible in a single 3T SWI slice by aligning adjacent slices with the current slice and predicting their difference fields. The downstream task innovatively combines clinical knowledge with brain substructure diagrams to selectively enhance clinically relevant features. When evaluated on a dataset comprising 97 cases (5495 slices), the proposed method achieved a Peak Signal-to-Noise Ratio (PSNR) of 23.05 dB and a Structural Similarity Index (SSIM) of 0.688. Due to the absence of specific methods for 7T SWI, our method was compared with existing enhancement techniques for general 7T MRI synthesis, outperforming these techniques in the context of 7T SWI synthesis. Clinical evaluations have shown that our synthetic 7T SWI is clinically effective, demonstrating its potential as a clinical tool.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.media.2024.103184 | DOI Listing |
J Med Chem
January 2025
Foghorn Therapeutics, 500 Technology Square, Suite 700, Cambridge, Massachusetts 02139, United States.
BRM (SMARCA2) and BRG1 (SMARCA4) are mutually exclusive ATPase subunits of the mSWI/SNF (BAF) chromatin remodeling complex. BAF is an attractive therapeutic target because of its role in transcription, and mutations in the subunits of BAF are common in cancer and neurological disorders. Herein, we report the discovery of compound () as a potent allosteric inhibitor of the dual ATPase subunits from a high-throughput screening hit with a BRM IC of ∼27 μM.
View Article and Find Full Text PDFMed Phys
January 2025
State Key Laboratory of Oncology in South China, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, P. R. China.
Mod Pathol
January 2025
Department of Dermatology, Feinberg School of Medicine, Northwestern University, Chicago, IL. Electronic address:
Deep penetrating nevi (DPNs) are characterized by activating mutations in the MAP kinase and Wnt/beta-catenin pathways that result in large melanocytes with increased nuclear atypia, cytoplasmic pigmentation, and often mitotic activity. Together with a lack of maturation, this constellation of findings creates challenges for pathologists to distinguish deep penetrating nevus (DPN) from DPN-like melanoma. To assess the utility of next generation sequencing (NGS) in resolving this diagnostic dilemma, we performed NGS studies on 35 lesions including 24 DPNs and 11 DPN-like melanomas to characterize the specific genomic differences between the two groups and elucidate the genetic events involved in malignant transformation of DPNs.
View Article and Find Full Text PDFEur J Cancer
November 2024
David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA.
Purpose: MAK683, a first-in-class and highly selective allosteric inhibitor of the embryonic ectoderm development subunit of polycomb repressive complex 2, has shown sustained antitumor activity in tumor xenograft models. This first-in-human phase 1/2 study evaluated the safety, pharmacokinetics (PK), and clinical activity of single-agent MAK683 in advanced malignancies.
Methods: MAK683 was administered fasted once daily or twice daily continuously in 28-day treatment cycles.
J Magn Reson Imaging
January 2025
Department of Radiology, Fortis Memorial Research Institute, Gurugram, India.
Background: Isocitrate dehydrogenase (IDH) wild-type (IDH) glioblastomas (GB) are more aggressive and have a poorer prognosis than IDH mutant (IDH) tumors, emphasizing the need for accurate preoperative differentiation. However, a distinct imaging biomarker for differentiation mostly lacking. Intratumoral thrombosis has been reported as a histopathological biomarker for GB.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!